Multiple myeloma trials in Italy

In Italy 74 Also abroad 703

74 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Where
Bologna, Milan, Naples, Rozzano, Torino
Age
18 years and over
People
508 worldwide
Run by
AstraZeneca
See details and how to joinNCT07391657
Phase 3Taking people
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Bari, Bologna, Bolzano, Milan, Novara, Palermo, Pescara, Rimini, Varese
Age
18 years and over
People
700 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07518186
No phaseTaking people
A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)
Where
Ancona, Bari, Bologna, Brescia, Catania, Florence, Genova, Milan, Monza, Naples, Novara, Parma, Pavia, Rimini, Roma, San Giovanni Rotondo, Terni, Torino, Udine, Varese
Age
18 years and over
People
1,900
Run by
Fondazione EMN Italy Onlus
See details and how to joinNCT05001087
No phaseNot yet taking people in Italy
Validating DW-MRI and Fat Fraction in Multiple Myeloma Post-ASCT: The RAC-FAT Study"
Where
Bari, Bologna, Brescia, Castelfranco Veneto, Como, Milan, Novara, Pavia, Rome
Age
18 years and over
People
92
Run by
Fondazione EMN Italy Onlus
See details and how to joinNCT07746232
Phase 3Not yet taking people in Italy
A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma
Where
Bologna, Milan, Rome, Rozzano, Turin
Age
18 years and over
People
234 worldwide
Run by
AstraZeneca AB
See details and how to join2025-524014-29-00 · EU 2025-524014-29-00
Phase 1Not yet taking people in Italy
A Phase 1 Study of TT125-802 as Monotherapy and in Combination with Pomalidomide and Dexamethasone in Participants with Multiple Myeloma
Where
Bologna, Milan
Age
18 years and over
People
25 worldwide
Run by
TOLREMO therapeutics AG
See details and how to join2025-523536-39-00 · EU 2025-523536-39-00
No phaseTaking people
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Where
Bologna, Bolzano, Brindisi, Florence, Lecce, Milan, Naples, Palermo, Roma, Salerno, Treviso, Trieste, Verbania, Vicenza
Age
18 years and over
People
900 worldwide
Run by
Janssen-Cilag Ltd.
See details and how to joinNCT06285318
Phase 1Taking people
A study to evaluate the Safety, Pharmacokinetics, and Activity of Subcutaneous Cevostamab (BFCR4350A) in Patients with Relapsed or Refractory Multiple Myeloma (CAMMA 3)
Where
Bologna, Rozzano
Age
18 years and over
People
45 worldwide
Run by
Genentech Inc.
See details and how to join2023-503404-89-00 · EU 2023-503404-89-00
Phase 3Taking people
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Where
Bologna, Catania, Genoa, Meldola, Milan, Monza, Rome
Age
18 years and over
People
893 worldwide
Run by
Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00
Phase 3Taking people
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Where
Ancona, Bologna, Florence, Legnano, Meldola, Milan, Palermo, Pescara, Pisa, Turin
Age
18 years and over
People
492 worldwide
Run by
Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00
No phaseTaking people
Real-life Study on the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory Multiple Myeloma
Where
Chieti
Age
18 years and over
People
60
Run by
Università degli Studi 'G. d'Annunzio' Chieti e Pescara
See details and how to joinNCT07777406
Phase 1/2Taking people
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Where
Bologna, Milan, Rome
Age
18 years and over
People
123 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT05714839 · EU 2022-501941-63-00
Phase 1Taking people
Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies
Where
Milan
People
7 worldwide
Run by
USWM Ct LLC
See details and how to join2024-513033-21-00 · EU 2024-513033-21-00
Phase 3Taking people
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Where
Bologna, Milan, Rome, Rozzano, Torino
Age
18 years and over
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07764978
Phase 3Taking people
A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.
Where
Bologna, Milan, Naples, Rozzano, Turin
Age
18 years and over
People
153 worldwide
Run by
AstraZeneca AB
See details and how to join2025-523285-25-00 · EU 2025-523285-25-00
Phase 2Taking people
A multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma
Where
Bari, Bergamo, Florence, Genoa, Meldola, Messina, Novara, Padova, Parma, Pavia, Pescara, Udine
Age
18 years and over
People
105 worldwide
Run by
European Myeloma Network B.V.
See details and how to join2023-505775-70-00 · EU 2023-505775-70-00
Phase 3Not yet taking people in Italy
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Where
Meldola
Age
18 years and over
People
520 worldwide
Run by
AbbVie
See details and how to joinNCT07728188 · EU 2026-525596-11-00
No phaseNot yet taking people in Italy
INfections in Patients Treated With CAR-T
Where
Bologna
Age
18 years and over
People
290
Run by
IRCCS Azienda Ospedaliero-Universitaria di Bologna
See details and how to joinNCT07713511
Phase 1/2Taking people
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Where
Bergamo, Meldola, Milan, Naples, Ravenna, Turin
Age
18 years and over
People
88 worldwide
Run by
AbbVie Deutschland GmbH & Co. KG
See details and how to join2025-525105-20-00 · EU 2025-525105-20-00
Phase 2Taking people
A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma
Where
Alexandria, Ascoli Piceno, Genoa, Meldola, Milan, Pavia, Ravenna
Age
18 years and over
People
116 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06140524 · EU 2023-505242-25-00
No phaseTaking people
Anonymization of Clinical Data From Pseudonymized Databases Collected as Part of Previus Clinical Trials on Multiple Myeloma
Where
Bologna
Age
18 years and over
People
600
Run by
IRCCS Azienda Ospedaliero-Universitaria di Bologna
See details and how to joinNCT07283224
No phaseTaking people
MMAPPIN' Study: Multiple Myeloma Analysis For Patient-specific Insights to Dissect Disease Heterogeneity
Where
Bologna
Age
18 years and over
People
520
Run by
IRCCS Azienda Ospedaliero-Universitaria di Bologna
See details and how to joinNCT07582354
Early phase 1Taking people
Single Microdose Trial- CXCR4 PET Tracer - Pharmacokinetics and Pharmacodynamics of [68Ga]Ga-R54, a Radiopharmaceutical Directed Toward CXCR4 in Patients With Advanced Solid Neoplasia.
Where
Naples
Age
18 years and over
People
10
Run by
National Cancer Institute, Naples
See details and how to joinNCT07577206 · EU 2024-513303-14-00
No phaseTaking people
One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS
Where
Pavia
Age
18 years to 99 years
People
100
Run by
Fondazione IRCCS Policlinico San Matteo di Pavia
See details and how to joinNCT07448935
No phaseTaking people
Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution
Where
Bologna, Catania, Palermo, Reggio Emilia
Age
18 years and over
People
60
Run by
Azienda USL Reggio Emilia - IRCCS
See details and how to joinNCT07214324